Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans

Lilly | June 01, 2020

Eli Lilly and Company (NYSE: LLY) today announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19. This investigational medicine, referred to as LY-CoV555, is the first to emerge from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in just three months after AbCellera and the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID) identified it from a blood sample taken from one of the first U.S. patients who recovered from COVID-19. LY-CoV555 is the first potential new medicine specifically designed to attack SARS-CoV-2, the virus that causes COVID-19. The first patients in the study were dosed at major medical centers in the U.S., including NYU Grossman School of Medicine and Cedars-Sinai in Los Angeles. "We are committed to working with our industry partners to generate scientific evidence to meet the urgent need for treatments that reduce the severity of COVID-19 disease," said Mark J. Mulligan, MD, director of the Division of Infectious Diseases and Immunology and director of the Vaccine Center at NYU Langone Health. "Antibody treatments like the one being studied here hold promise to be effective medical countermeasures against this deadly infection," said Dr. Mulligan, also the Thomas S. Murphy, Sr. Professor in the Department of Medicine at NYU Langone.

Spotlight

Learn how stem cells help regenerate cartilage and slow down degenerative arthritis.

Spotlight

Learn how stem cells help regenerate cartilage and slow down degenerative arthritis.

Related News

INDUSTRIAL IMPACT

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio

MeMed | January 10, 2022

MeMed, a leader in host response technologies, announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission. Funds will be used to scale up manufacturing, accelerate commercialization and expand MeMed’s pioneering host immune response product portfolio. MeMed’s technology suite decodes the body’s immune response within minutes, providing physicians with important patient management solutions that tackle key clinical dilemmas. The U.S. Food and Drug Administration (FDA) recently granted a landmark clearance for the use of the MeMed BV® test on the point-of-need platform MeMed Key®, to help healthcare providers distinguish between bacterial and viral infections in both children and adults. MeMed has also developed the MeMed COVID-19 Severity™ test for predicting severe outcomes in COVID-19 patients, which has been cleared for use in Europe. The latest financing brings together new and existing investors including Horizons Ventures, Shavit Capital, Social Capital, La Maison Partners, Touchwood Capital, Caesara Medical Holdings, Union Tech Ventures, ClaI Insurance, Phoenix Insurance, Poalim Equity and Western Technology Investment. “This new investment will enable MeMed to expand operations with a focus on the U.S. We are grateful to our investors for their support and will leverage the funds, the recent FDA clearance, and our growing network of partnerships to provide broad patient access to our technology, as well as expand our product portfolio of pioneering host response solutions.” Eran Eden, MeMed’s co-founder and CEO Patrick Zhang, Horizons Ventures, said: “We strongly believe that MeMed’s strategy of using host immune response technologies is a significant advance in the improvement of two major issues in healthcare today: the rise of antimicrobial resistance due to unnecessary prescription of antibiotics and effectively triaging patients infected with COVID-19. We look forward to playing a role in how MeMed, a category leader in this area, is transforming the way diseases are diagnosed and treated to improve patient healthcare across the globe.” About MeMed Our mission is to translate the immune system's complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society.

Read More

CELL AND GENE THERAPY

Elastrin Therapeutics Announces Newly Formed Scientific Advisory Board

Elastrin Therapeutics Inc. | January 17, 2022

Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board. The Board is comprised of leading industry and university experts in cardiovascular research and clinical development. Former CMO of Elastrin Therapeutics, Dr. Pedro M. Quintana Diez, will act as chairman. Elastrin Therapeutics’ lead asset ELT-001 is an EDTA-loaded nanoparticle conjugated with a proprietary monoclonal antibody for the treatment of vascular calcification. “We are fortunate to work with such an amazing group of medical scientists, cardiovascular experts and pharma executives on our Scientific Advisory Board,” said Dr. Matthias Breugelmans, CEO of Elastrin Therapeutics. “The members bring a remarkable understanding of cardiovascular research, as well as deep expertise in the development of clinical drugs.” “Elastrin is a prime example of what Kizoo is looking for in its investments: Not delaying an age-related disease but reversing it,” Patrick Burgermeister, Partner at Kizoo Technology Capital and member of Elastrin Therapeutics’ Board of Directors Elastrin Therapeutics’ Scientific Advisory Board is comprised of: Prof. Charles O'Neill, MD: Dr. O’Neill has had an active basic and clinical research program in vascular calcification for the past 20 years and has published over 45 articles on this subject. As a practicing nephrologist, he has a particular interest in vascular calcification in patients with chronic kidney disease. Current research is aimed at approaches to assess reversibility of calcification in animal models and to slow progression of calcification by altering hemodialysis prescription in clinical trials. Prof. Elena Aikawa, MD, PhD: Dr. Elena Aikawa is a Professor of Medicine at Harvard Medical School, and the Naoki Miwa Distinguished Chair in Cardiovascular Medicine and the Director of Heart Valve Translational Research Program at Brigham and Women’s Hospital. She was at the forefront in the discovery of inflammation-dependent mechanisms of cardiovascular calcification. Her studies contributed to the discovery of calcifying extracellular vesicles as a precursor of microcalcification. Prof. Frank Rutsch, MD: Frank Rutsch is an Associate Professor in Pediatrics at Münster University Children’s Hospital, Münster, Germany. After a postdoctoral research fellowship at the University of California, San Diego, he became the leader of an independent research group at Münster University Children’s Hospital in 2004. Dr. Rutsch’s main research interests are focused on the discovery of the underlying genetic defects and translational aspects in rare pediatric metabolic and autoimmune disorders. Dr. Klaus-Dieter Langner: Klaus-Dieter Langner is a life science expert with more than 32 years of experience in pharmaceutical industry. Klaus started his career as research scientist at Behringwerke/Hoechst focusing on the expression of recombinant human plasma proteins and immunomodulators. After 12 years, he moved to Grünenthal where he was appointed as Head of Research. In his last position, Klaus acted as Chief Scientific Officer and Member of the Corporate Executive Board. Prof. Linda Hands, MD: Linda Hands was appointed Clinical Reader in the University of Oxford and Honorary Consultant Vascular surgeon in 1992 after training in London, Oxford and Chicago. She was Clinical Director of Vascular and cardiothoracic surgery for three years and also served on the Health Authority and a NICE committee. Linda retired in late 2017 as Associate Professor and remain an Hon. Emeritus Professor at the John Radcliffe Hospital Oxford and Emeritus Fellow of Green College, Oxford. Dr. Pedro M. Quintana Diez, M.D.: Pedro is an internal medicine doctor with over 20 years of clinical development experience in the international biotech and pharmaceutical industry. Prior to joining Elastrin Therapeutics, Pedro served as CMO of Sensory Sciences LLC and held VP and leadership positions at Grunenthal, Abbvie and ParinGenix. Pedro managed Phase II and III developments in cardiovascular and lung diseases. His experience submitting INDs and CTAs will add further value to the company’s pipeline. Dr. Yuri Martina, MD, MBA: Yuri has more than 20 years of experience and a strong track record in the strategic and operational leadership of all phases of clinical research and development at companies across Europe and the US. During his career, Yuri has worked actively in different therapeutic areas and he has led teams bringing multiple compounds from pre-clinical phase into clinical studies in both Europe and US, and achieved multiple successful NDA and MAA submissions and approvals. About Elastrin Therapeutics Inc. Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University. The team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting. About KIZOO Kizoo provides seed and follow-on financing with a focus on rejuvenation biotech. Having been entrepreneurs, VC, and mentors in both high-growth tech and biotech companies ourselves for many years with multiple exits and massive value created for the founders, Kizoo now brings this experience to the emerging field of rejuvenation biotech. We see it as a young industry that will eventually outgrow today's largest technology markets.

Read More

AI

Viva Biotech and BioMap Have Signed a Strategic Collaboration Agreement to Accelerate Early Drug Discovery Using AI Technology

Viva Biotech, BioMap | May 11, 2021

The first generation of the China Biocomputing Conference, hosted by BioMap and Adock, was successfully launched in Suzhou. The conference's goal is to bring together biotech and IT industry partners to build a multi-party integrated industrial ecosystem and realize AI's full potential in the field of biotechnology. Viva Biotech was invited to the conference and announced a strategic alliance with BioMap. This alliance will combine BioMap's AI + biological computing engine with Viva Biotech's structure-based drug discovery tool to jointly accelerate the R&D of novel drugs. Viva Biotech's President, Dr. Delin Ren, stated: "The combination of AI deep learning technologies and the SBDD technology platform is certain to have far-reaching consequences for drug design and R&D. The strategic partnership between Viva Biotech and BioMap is the ideal combination between these two technologies. It is anticipated that it will shorten the R&D period and increase the success rate of novel drug discovery." "High-quality biological data is the base of biocomputing platform development," said Liu Wei, co-founder, and CEO of BioMap. Viva Biotech has the most advanced protein structure analysis technologies and capabilities in the world. The partnership with Viva Biotech will allow BioMap to obtain high-quality macromolecular structure data in a high-throughput manner, especially for new targets, artificially designed antibody molecules, and target-drug complexes. The partnership, when combined with BioMap's strong computing power and algorithm development expertise, is expected to facilitate the development of BioMap's AI macromolecular drug platform, which will potentially lead to new drug development." AlxplorerBio and EPN, two biotech firms that Viva BioInnovator funded in and incubated, both attended the meeting and signed the collaboration agreement. About Viva Biotech Viva Biotech aims to become a place for innovative biotechnology companies from around the world. We have built a scalable business model that combines the conventional cash-for-service (CFS) model with the revolutionary equity-for-service (EFS) model. Under the CFS model, the Group offers global pharmaceutical clients a one-stop-shop for new drug discovery and production. The EFS business is committed to investing globally in biotech research that provides novel solutions to unmet medical needs in a variety of therapeutic areas. Viva Biotech has offered drug development and manufacturing services to 1,252 pharmaceutical clients worldwide as of December 31, 2020, worked on over 1,500 independent drug targets, delivered over 21,000 independent protein structures, and incubated/invested in 67 biotech firms. About BioMap BioMap is China's first biocomputing-driven biotech firm, led as chairman by Baidu CEO Robin Li and co-founder and CEO by Baidu Ventures' former CEO Liu Wei. BioMap was established during a period of growth in biological data. Our goal is to use AI and data to significantly improve the lives of patients. BioMap, positioned as a data-driven company, is speeding the R&D phase of early screening/diagnosis, drug discovery, and other precision medicine products by leveraging high-performance biocomputing and AI capabilities, gaining insights from our unique and vast library of population and molecular data sets. We are concentrating our efforts on developing our internal AI engine and data collection capabilities to curate our proprietary insights for difficult diseases.

Read More